Ubliuximab +TGR-1202 Demonstrates Activity and Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL. By admin / 06/02/2015
Safety and Activity of the Chemotherapy-free Triplet of Ublituximab, TGR-1202 and ibrutinib in Relapsed B-cell Malignancies. By admin / 06/02/2015
Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Combination with TGR-1202, a Next Generation Once Daily PI3K Delta Inhibitor, Demonstrate Activity in Heavily Pre-Treated and High-Risk Chronic Lymphocytic Leukemia (CLL) and B-Cell Lymphoma. By admin / 12/09/2014
A Phase I Trial of Ublituximab, A Novel Glycoengineered Anti-CD20 mAb, In Combination With TGR-1202, A Next Generation PI3K Delta Inhibitor, In Patients With Chronic Lymphocytic Leukemia And Non-Hodgkin’s Lymphoma. By admin / 07/21/2014
